Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04860297
Other study ID # mRNA-1273-P304
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date April 16, 2021
Est. completion date May 22, 2023

Study information

Verified date September 2023
Source ModernaTX, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is an open-label study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1273 Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) vaccine in adults with a kidney or liver solid organ transplant (SOT) and in healthy adult participants. The primary goal of the study is to evaluate the safety of mRNA-1273 and the serum antibody (Ab) responses obtained 28 days after the last dose of mRNA-1273.


Recruitment information / eligibility

Status Completed
Enrollment 234
Est. completion date May 22, 2023
Est. primary completion date May 22, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Transplant Recipients Key Inclusion Criteria for Part A: - Is either a kidney or a liver transplant recipient who is at least 90 days after transplantation at the time of consent, and is either unvaccinated or previously vaccinated with 2 doses of Moderna COVID-19 vaccine who is at least 1 month after the second dose at the time of consent. Participants who received the 2 doses of Moderna COVID-19 vaccine before transplant are not eligible. - Understands, agrees, and is able to comply with the study procedures and provides written informed consent. - Received chronic immunosuppressive therapy for the prevention of allograft rejection for a minimum of 90 days before signing consent, including but not limited to: glucocorticoids (such as, prednisolone), immunophilin binding agents (such as, calcineurin inhibitors, mTOR inhibitors), or inhibitors of de novo nucleotide synthesis (such as, mycophenolic acid, mizoribine, leflunomide, azathioprine). - For female participants of childbearing potential: negative pregnancy test, adequate contraception or has abstained from all activities that could result in pregnancy for at least 28 days prior to the first injection, agreement to continue adequate contraception or abstinence through 3 months following the second dose (Day 29) for those receiving 2-dose regimen and, through 3 months following the third dose (Day 85) for those receiving 3-dose regimen, and through 3 months following the third dose (Day 1) for those previously vaccinated SOT participants, and not currently breastfeeding. - Is medically stable, according to investigator's judgment, during the 3 months before signing consent. Key Exclusion Criteria for Part A: - Has prior or planned administration of a coronavirus vaccine (for example, SARS-CoV-2 [for unvaccinated participants only], SARS-CoV, or MERS [Middle East Respiratory Syndrome] -CoV vaccine). - Has current treatment with investigational agents for either prophylaxis against COVID-19 (for unvaccinated participants only) or treatment of COVID-19 (such as, anti-SARS-CoV-2 monoclonal antibodies). - A history of more than one solid organ transplanted (such as, kidney and pancreas). A history of previous kidney or liver transplant is acceptable. - Has received therapies that have depleting properties on T cells, B cells, and plasma cells (examples of depletional therapies include, but are not limited to, antithymocyte globulin [ATG], monoclonal antibodies, and proteosome inhibitors) within the last 3 months prior to enrollment. - A history of biopsy-proven T-cell- or Ab-mediated rejection within 3 months of informed consent, or suspected active or chronic rejection according to the investigator's judgment. - Has a known close contact with anyone with laboratory confirmed SARS-CoV-2 infection within 2 weeks to vaccine administration or known history of SARS-CoV-2 infection or positive SARS-CoV-2 test. - Has a medical, psychiatric, or occupational condition that may pose additional risk as a result of participation or that could interfere with safety assessments or interpretation of results according to the investigator's judgment. - Has a history of clinically relevant donor-specific Ab. - Has a history of complications of immunosuppression - Suspected clinically relevant active hepatitis, including viral hepatitis, according to the investigator's judgment - Known human immunodeficiency virus (HIV) infection - Has a history of a diagnosis or condition that, in the judgment of the investigator, may affect study endpoint assessment or compromise participant safety. - Received any non-study vaccine within 28 days before or after any dose of vaccine (except for seasonal influenza vaccine, which is not permitted within 14 days before or after any dose of vaccine) - Received intravenous blood products (red blood cells, platelets, immunoglobulins) within 3 months prior to Day 1. - Participated in an interventional clinical study within 28 days prior to Day 0 or plans to donate blood products while participating in this study. Healthy Participants Key Inclusion Criteria for Part A: - In good general health without current or previous diagnosis of immunocompromising condition, immune-mediated disease, or other immunosuppressive condition, according to investigator assessment, at the time of consent, and has not been vaccinated with any COVID-19 vaccine at the time of consent. - Understands, agrees, and is able to comply with the study procedures and provides written informed consent. - For female participants of childbearing potential: negative pregnancy test, adequate contraception or has abstained from all activities that could result in pregnancy for at least 28 days prior to the first injection (Day 1), agreement to continue adequate contraception or abstinence through 3 months following the second injection (Day 29), and not currently breastfeeding. - Is medically stable, according to investigator's judgment, during the 3 months before signing consent. Key Exclusion Criteria for Part A: - Has a known close contact with anyone with laboratory confirmed SARS-CoV-2 infection or COVID-19 within 2 weeks prior to vaccine administration or known history of SARS-CoV-2 infection or positive SARS-CoV-2 test. - Has prior or planned administration of a coronavirus vaccine (for example, SARS-CoV-2, SARS-CoV, or MERS-CoV vaccine). - Has current treatment with investigational agents for either prophylaxis against COVID-19 or treatment of COVID-19 (for example, anti-SARS-CoV-2 monoclonal antibodies). - Has a medical, psychiatric, or occupational condition that may pose additional risk as a result of participation or that could interfere with safety assessments or interpretation of results according to the investigator's judgment. - Has a history of a diagnosis or condition that, in the judgment of the investigator, may affect study endpoint assessment or compromise participant safety. - Received any non-study vaccine within 28 days before or after any dose of vaccine (except for seasonal influenza vaccine, which is not permitted within 14 days before or after any dose of vaccine) - Received intravenous blood products (red blood cells, platelets, immunoglobulins) within 3 months prior to Day 1. - Received systemic immunosuppressants or immune-modifying drugs for >14 days in total within 6 months prior to Screening (for corticosteroids =20 mg/day of prednisone equivalent). - Participated in an interventional clinical study within 28 days prior to Day 0 or plans to donate blood products while participating in this study. Inclusion Criteria for Part B: - Participants must have been previously enrolled in this study (mRNA-1273-P304), are actively participating in Part A, and at least 4 months from the last dose; or participant is either a kidney or a liver SOT recipient who is at least 90 days after transplantation at the time of consent and who completed primary vaccination series (3 doses for mRNA COVID-19 vaccine; 2 doses for non-mRNA COVID-19 vaccine or at least 1 dose of non-mRNA combined with 1 dose of mRNA COVID-19 vaccine) under the EUA who are at least 4 months from the last dose. All primary COVID-19 vaccination series must be completed after transplant. - Female participants of childbearing potential may be enrolled in the study if the participant has a negative pregnancy test on the day of the first injection (booster dose Day 1). Exclusion Criteria for Part B: - Exclusion Criteria in Part A will apply except: 1. prior or planned administration of a coronavirus vaccine and current treatment with investigational agents for either prophylaxis against COVID-19. 2. known close contact with anyone with laboratory-confirmed SARS-CoV-2 infection or COVID-19 within 2 weeks prior to vaccine administration or any known history of SARS-CoV-2 infection or positive SARSCoV-2 test will apply only to new SOT participants who will be enrolled in Part B.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
mRNA-1273
Sterile liquid for injection

Locations

Country Name City State
United States Piedmont Transplant Institute Atlanta Georgia
United States Brigham and Women's Hospital Boston Massachusetts
United States University of Cincinnati Cincinnati Ohio
United States Cleveland Clinic Hospital Cleveland Ohio
United States Northwell Health Manhasset New York
United States Aventiv Research Inc Mesa Arizona
United States Yale University School of Medicine New Haven Connecticut
United States Colombia University Medical Center New York New York
United States University of Nebraska Medical Center Omaha Nebraska
United States Hospital of The University of Pennsylvania Philadelphia Pennsylvania
United States Rhode Island Hospital Providence Rhode Island
United States California Institute of Renal Research San Diego California
United States University of Washington Medical Center Seattle Washington
United States Tampa General Medical Group Tampa Florida
United States University of Massachusetts Medical School Worcester Massachusetts

Sponsors (1)

Lead Sponsor Collaborator
ModernaTX, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs) in Part A Up to Day 92
Primary Number of Participants with Solicited Local and Systemic ARs in Part B Day 8
Primary Number of Participants with Unsolicited Adverse Events (AEs) in Part A Up to Day 113
Primary Number of Participants with Unsolicited AEs in Part B Day 29
Primary Number of Participants with Medically-Attended AEs (MAAEs) up to approximately 1 year
Primary Number of Participants with Serious AEs (SAEs) up to approximately 1 year
Primary Number of Participants with AEs of Special Interest (AESIs) up to approximately 1 year
Primary Number of Participants with AEs Leading to Withdrawal up to approximately 1 year
Primary Number of Participants with Biopsy-Proven Organ Rejection up to approximately 1 year
Primary Geometric Mean Titer (GMT) of SARS-CoV-2 Specific Neutralizing Antibody (nAb) for Participants in Part A 28 days after last dose (Day 57 for unvaccinated participants who received 2 doses, Day 113 for unvaccinated SOT participants who received 3 doses, and Day 29 for previously vaccinated SOT participants)
Primary GMT of SARS-CoV-2 Specific nAB for Participants in Part B 28 days after booster dose (booster dose Day 29)
Secondary Geometric Mean (GM) of SARS-CoV-2 Binding Antibody (bAb) for Unvaccinated Participants Receiving 2-Dose Regimen Day 1, 29, 57, 209, and 394
Secondary GM of SARS-CoV-2 bAb for Unvaccinated SOT Participants Receiving 3-Dose Regimen Day 1, 29, 57, 85, 113, 265, and 450
Secondary GM of SARS-CoV-2 bAb for Previously Vaccinated SOT Participants Day 1, 29, 180, and 365
Secondary Geometric Mean Fold Rise (GMFR) of bAb Relative to Day 1 for Unvaccinated Participants Receiving 2-Dose Regimen Day 29, 57, 209, and 394
Secondary GMFR of bAb Relative to Day 1 for Unvaccinated SOT Participants Receiving 3-Dose Regimen Day 29, 57, 85, 113, 265, and 450
Secondary GMFR of bAb Relative to Day 1 for Previously Vaccinated SOT Participants Day 29, 180, and 365
Secondary The GMT Values of SARS-CoV-2-Specific nAb for Unvaccinated Participants Receiving 2-Dose Regimen Day 1, 29, 209, and 394
Secondary The GMT Values of SARS-CoV-2-Specific nAb for Unvaccinated SOT Participants Receiving 3-Dose Regimen Day 1, 29, 85, 113, 265, and 450
Secondary The GMT Values of SARS-CoV-2-Specific nAb for Previously Vaccinated SOT Participants Day 1, 29, 180, and 365
Secondary GMFR of nAb Relative to Day 1 For Unvaccinated Participants Receiving 2-Dose Regimen Day 29, 57, 209, and 394
Secondary GMFR of nAb Relative to Day 1 for Unvaccinated SOT Participants Receiving 3-Dose Regimen Day 29, 57, 85, 113, 265, and 450
Secondary GMFR of nAb Relative to Day 1 for Previously Vaccinated SOT Participants Day 29, 180, and 365
Secondary Number of Transplant Recipients and Number of Healthy Participants (Who had a Negative SARS-CoV-2 at Baseline) with Asymptomatic SARS-CoV-2 Infection Clinical signs indicative of asymptomatic SARS-CoV-2 infection as predefined for the study. Day 43 up to Day 394 for unvaccinated participants who received 2 doses, Day 99 up to Day 450 for unvaccinated SOT participants who received 3 doses, and Day 15 up to Day 365 for previously vaccinated SOT recipients
Secondary Number of Transplant Recipients and Number of Healthy Participants with a First Occurrence of Symptomatic COVID-19 Starting 14 Days after the Second Dose of Vaccine and after the Third Dose of Vaccine Clinical signs indicative of symptomatic COVID-19 as predefined for the study. Day 43 up to Day 394 for unvaccinated participants who received 2 doses, Day 99 up to Day 450 for unvaccinated SOT participants who received 3 doses, and Day 15 up to Day 365 for previously vaccinated SOT recipients
Secondary Number of Transplant Recipients and Number of Healthy Participants with a First Occurrence of Severe COVID-19 Starting 14 Days after Second Dose of Vaccine and after the Third Dose of Vaccine Clinical signs indicative of severe COVID-19 as predefined for the study. Day 43 up to Day 394 for unvaccinated participants who received 2 doses, Day 99 up to Day 450 for unvaccinated SOT participants who received 3 doses, and Day 15 up to Day 365 for previously vaccinated SOT recipients
Secondary Number of Participants with a Change in Immunosuppressant Medications to Treat Organ Transplant Rejection or to Improve Immune Tolerance Change in immunosuppressant medication is defined as any of the following: -any adjustments (temporarily or permanently) in immunosuppressants; -addition of new immunosuppressants; -or switching from one maintenance rejection prophylaxis regimen to another Up to Day 394 for unvaccinated participants who received 2 doses, Up to Day 450 for unvaccinated SOT participants who received 3 doses, Up to Day 365 for previously vaccinated SOT recipients
See also
  Status Clinical Trial Phase
Active, not recruiting NCT06039449 - A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2 Phase 3
Completed NCT04512079 - FREEDOM COVID-19 Anticoagulation Strategy Phase 4
Completed NCT04527471 - Pilot Study of Ensifentrine or Placebo Delivered Via pMDI in Hospitalized Patients With COVID-19 Phase 2
Recruiting NCT05584202 - Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants Phase 2
Completed NCT04579549 - Repeat Testing for SARS-CoV-2 N/A
Active, not recruiting NCT05547243 - A Cohort Study of COVID-19 mRNA Vaccine, Bivalent in Participants in China N/A
Recruiting NCT04747574 - Evaluation of the Safety of CD24-Exosomes in Patients With COVID-19 Infection Phase 1
Recruiting NCT04613310 - PCR and Rapid Diagnostic Test on Saliva and Nasopharyngeal Swabs for the Detection of SARS-CoV-2 (COVID-19) N/A
Completed NCT04515147 - A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19 Phase 2
Terminated NCT04447404 - DUR-928 in Subjects With SARS-CoV-2 With Acute Lung, Liver or Kidney Injury Phase 2
Withdrawn NCT04388709 - Interferon Lambda Therapy for COVID-19 Phase 2
Active, not recruiting NCT05550142 - A Preliminary Exploratory Cohort Study of SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine in Participants Aged 18 Years and Over in China N/A
Completed NCT04620798 - Longitudinal COVID-19 Antibody Testing in Indiana University Undergraduate Students N/A
Active, not recruiting NCT05547256 - A Preliminary Exploratory Cohort Study of COVID-19 mRNA Vaccine, Bivalent in Participants Aged 18 Years and Over in China N/A
Completed NCT04561102 - Evaluation of the COVIDSeq Test in Nasal Swab and Saliva From a COVID-19 Asymptomatic Population
Completed NCT04452604 - Multicentric Registry of Patients With Acute Leukemia Infected by COVID-19
Completed NCT05366322 - A Study to Compare mRNA-1273 Versus BNT162b2 COVID-19 Vaccines Among Immunocompromised Adults
Completed NCT04526769 - Detecting SARS-CoV-2 in Tears
Terminated NCT04958304 - Moderna COVID-19 Vaccine mRNA-1273 Observational Pregnancy Outcome Study
Completed NCT04690413 - NOWDx Test for the Detection of Antibodies to COVID-19 N/A